Topical antisense elements - Suono Bio
Latest Information Update: 28 Mar 2026
At a glance
- Originator Suono Bio
- Class Antisense elements
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2026 No recent reports of development identified for research development in Unspecified in USA (Intradermal)
- 25 Feb 2022 Early research in Unspecified in USA (Intradermal) before February 2022 (Suono Bio pipeline, February 2022)
- 01 Dec 2021 Suono Bio enters into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital related to Formulation-Independent Drug Delivery in USA